Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chugai Announced New Mid-Term “Sunrise 2012” Plan

This article was originally published in PharmAsia News

Executive Summary

Chugai President Naoru Nagayama announced a new mid-term business plan, Sunrise 2012, at a Jan. 30 briefing to stave off a lowered profit target from ¥100 billion to ¥80 billion. He said he is still optimistic about maximum value generation from the company's new products, and that its alliance with Roche has reinforced its cancer drug pipeline. In 2007, three new products - Avastin, Tarceva and Copegus went on sale. Chugai's IL-6 receptor antibody Actemra also was submitted for approval overseas. Nagayama said these developments indicated the portfolio is bearing fruit. Chugai will also strengthen marketing and sales operations, and will set up a portfolio management committee and strategic marketing committee, aiming to defend market shares for current products and realize maximum valuation for new cancer treatments. (Click for more-Japanese language

You may also be interested in...

UK Supplements Marketer Makes No Effort To Back Up Ad Claims

The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.

COVID-19: New Emergency Guidance From AAMI Targets Remote-Controlled Devices

Consensus report CR511 from the Association for the Advancement of Medical Instrumentation highlights common system elements for engineers, and outlines safety and risk-control measures that manufacturers and caregivers should consider.

Radical Shake-Up In Store For Entire EU Pharma Legislation

The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts